Lymphomas are the second most common cancers after leukemias seen in children in Turkey, although they rank third in many western countries. Ninety-seven patients with newly diagnosed, untreated non-Hodgkin's lymphoma, between April 1994 and December 1997, were included in this study. Modified lymphoma malign B (LMB) and lymphoma malign T (LMT) regimens were used for treatment of B- and T-cell disease, respectively. Ten (10.3%), 68 (70.1%), and 19 (19.6%) patients had stage II, HI, and IV disease, respectively. Forty-eight, 19, 15, 9, 5, and I patients had tumors at abdominal, mediastinal, disseminated, head and neck, extranodal, and peripheral nodal locations, respectively. Seventy-two patients were treated with LMB89 regimen and 25 were treated with LMT89 regimen. Thirty-four patients had tumor lysis at diagnosis, and 9 patients required dialysis. Objective response rates were 75% for patients treated by LMB regimen and 92% for those treated by LMT regimen. Two-year overall survival rates were 90, 66 1, and 50.8% for patients with stage 11, 111, and IV disease, respectively. Two-year overall survival rates were 64.2% for LMB-treated patients, and 70.8% for LMT-treated patients. Poor response at the end of cytoreductive treatment and age younger than 4 years were poor prognostic factors. Pediatric lymphomas could be treated safely and effectively by LMB and LMT regimens.